UPDATE: BMO Capital Markets Downgrades NuVasive to Underperform, Raises PT on Multiple Positive Factors

Loading...
Loading...
In a report published Monday, BMO Capital Markets analyst Joanne K. Wuensch downgraded the rating on
NuVasiveNUVA
from Market Perform to Underperform, but raised the price target from $18.00 to $22.00. In the report, BMO Capital Markets noted, “We are downgrading shares of NUVA to Underperform from Market Perform, given 1) the significant recovery in the stock since its 3Q12 miss (the stock is up 73% YTD), 2) a stable, but not robust spine market, and 3) a pattern over the past four years for the stock to trade up in the 1H of the year and down in the 2H (while the stock has meaningfully recovered YTD, it is just 10% higher than where it was a year ago, with a big swoon in between, versus an 18% rise in the S&P 500).” NuVasive closed on Friday at $26.70.
Posted In: Analyst ColorDowngradesAnalyst RatingsBMO Capital MarketsJoanne K. Wuensch
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...